Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone

被引：1

作者：

Yoo, H. H. ^{[1
]}

Kim, N. S. ^{[2
]}

Lee, J. ^{[1
]}

Sohn, D. R. ^{[3
]}

Jin, C. ^{[1
]}

Kim, D. H. ^{[1
]}

机构：

[1] Korea Inst Sci & Technol, Doping Control Ctr, Seoul 136791, South Korea

[2] Korea Food & Drug Adm, Res Planning & Management Team, Seoul, South Korea

[3] Soonchunhyang Univ, Coll Med, Dept Clin Pharmacol, Cheonan, South Korea

来源：

XENOBIOTICA | 2009年 / 39卷 / 01期

关键词：

Eperisone; in vitro metabolism; cytochrome P450s (CYPs); human liver microsome; human intestinal microsome; METABOLISM;

D O I：

10.1080/00498250802509448

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Eperisone is a centrally acting muscle relaxant widely used for the therapeutic treatment of spastic patients to relieve muscle stiffness and back pain. The objective of this study was to characterize the metabolic pathway involved in the biotransformation of eperisone mediated by human cytochrome P450 (CYP) enzymes. Eperisone was metabolized to seven metabolites via oxidation and carbonyl reduction in human liver microsome. Among them, M3 and M4 were found to be primary major metabolites which were generated by CYPs. The kinetics study with (-)-R- and (+)-S-eperisones revealed that CYPs-mediated hydroxylation did not have significant stereoselectivity for metabolic clearance of eperisone. Incubation with recombinant CYP isozyme, chemical inhibition assay, and immuno-inhibition assay showed that multiple CYPs were involved in M4 formation, but mainly CYP2J2 in M3 formation. In addition, intestinal microsomes metabolized eperisone to M3 and M4 via CYP2J2- and CYP3A4-mediated reactions, which are supposed to contribute to presystemic metabolism of eperisone.

引用

页码：1 / 10

页数：10

共 12 条

[1] The pharmacokinetics of levosalbutamol - What are the clinical implications? [J].

Boulton, DW ;

Fawcett, JP .

CLINICAL PHARMACOKINETICS, 2001, 40 (01) :23-40

[2]

Fujita T, 1981, PHARMACOMETRICS, V21, P835

[3]

Hasegawa Y, 1992, Eur Neuropsychopharmacol, V2, P157, DOI 10.1016/0924-977X(92)90026-5

[4] The small intestine as a xenobiotic-metabolizing organ [J].

Kaminsky, LS ;

Zhang, QY .

DRUG METABOLISM AND DISPOSITION, 2003, 31 (12) :1520-1525

[5] Stereoselectivity in drug metabolism [J].

Lu, Hong .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2007, 3 (02) :149-158

[6] Long-lasting muscle relaxant activity of eperisone hydrochloride after percutaneous administration in rats [J].

Matsunaga, M ;

Uemura, Y ;

Yonemoto, Y ;

Kanai, K ;

Etoh, H ;

Tanaka, S ;

Atsuta, Y ;

Nishizawa, Y ;

Yamanishi, Y .

JAPANESE JOURNAL OF PHARMACOLOGY, 1997, 73 (03) :215-220

[7] Intestinal first-pass metabolism of eperisone in the rat [J].

Mihara, K ;

Matsumura, M ;

Yoshioka, E ;

Hanada, K ;

Nakasa, H ;

Ohmori, S ;

Kitada, M ;

Ogata, H .

PHARMACEUTICAL RESEARCH, 2001, 18 (08) :1131-1137

[8] The human intestinal cytochrome P450 "pie" [J].

Paine, MF ;

Hart, HL ;

Ludington, SS ;

Haining, RL ;

Rettie, AE ;

Zeldin, DC .

DRUG METABOLISM AND DISPOSITION, 2006, 34 (05) :880-886

[9] DETERMINATION OF EPERISONE IN HUMAN PLASMA BY GAS-CHROMATOGRAPHY MASS-SPECTROMETRY [J].

TAKAMATSU, T ;

YAMAZAKI, K ;

KAYANO, M ;

TAKENAKA, F ;

HASUI, M ;

OHKAWA, T .

JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 584 (02) :261-266

[10]

TAKAMATSU T, 1993, IYAKUHIN KENKYU, V24, P520

← 1 2 →